Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 17Unknown 11Recruiting 6Active not recruiting 6Terminated 5Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 21Nasopharyngeal Carcinoma 11Squamous Cell Carcinoma of Head and Neck 9Small Cell Lung Carcinoma 9Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 5Esophageal Squamous Cell Carcinoma 5Biliary Tract Neoplasms 5Lung Neoplasms 4Cholangiocarcinoma 4Stomach Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Neoplasms 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Recurrence 2Ovarian Neoplasms 2Neoplasms 2NSCLC 2Esophageal Neoplasms 2Breast Neoplasms 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Tongue Squamous Cell Carcinoma 1Thyroid Neoplasms 1Thymoma 1Thymic epithelial tumor 1Solid Tumor Cancer 1Rare Tumour 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Cisplatin × Clear all
NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3 Not yet recruiting
424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
368 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡